临床荟萃

• 专题 • 上一篇    下一篇

风湿免疫病生物制剂治疗进展

  

  1. 河北医科大学第二医院免疫风湿科,河北石家庄050000
  • 出版日期:2016-05-05 发布日期:2016-05-04
  • 通讯作者: 靳洪涛,Email:15803210963@163.com
  • 作者简介:靳洪涛,男,52岁,河北医科大学第 二医院免疫风湿科主任,主任医师,教授, 硕士生导师。现任中华医学会风湿病学 分会委员,中国免疫学会临床免疫分会委 员,中国医师协会风湿免疫科医师分会委 员,海峡两岸医药卫生交流协会风湿免疫 病学专家委员会委员,河北省免疫学会常 务理事,河北省免疫学会风湿免疫专业委 员会主任委员,河北省医学会风湿病分会副主任委员,石家庄 市医学会风湿免疫专业委员会主任委员,《医学参考版》风湿 免疫频道编委。

Therapeutic advancements of biologic agents in rheumatic disease

  1. Department of Immunology and Rheumatology, the Second Hospital of Hebei Medical University,Shijiazhuang 050000,China
  • Online:2016-05-05 Published:2016-05-04
  • Contact: Corresponding author: Jin Hongtao,Email: 15803210963@163.com

摘要: 生物制剂是一种选择性针对参与免疫反应或炎症过程的分子或以受体为靶目标的单克隆抗体或天然抑
制分子的重组产物。生物制剂种类繁多,主要针对细胞因子,B细胞和共刺激信号分子,包括:肿瘤坏死因子抑制剂、
抗白细胞介素6(IL-6)受体单克隆抗体和抗CD20单克隆抗体利妥昔单抗等多种药物,主要用于治疗强直性脊柱炎、
类风湿关节炎和系统性红斑狼疮等自身免疫性疾病。生物制剂的使用应关注其安全性,用药前进行结核筛查,除外活
动性感染和肿瘤。生物制剂的减停药问题有待探讨。

关键词: 生物制品, 肿瘤坏死因子类, 关节炎,类风湿, 脊柱炎

Abstract:

Biological agent is a recombinant product that is selectively targeted to the immune response or to the inflammatory process, or to the target of a monoclonal antibody or a natural inhibitor of the target. The biologic drugs have wide variety, the major targets of most biologic therapies are cytokines, B cells and costimulation molecules, including tumor necrosis factor (TNF) inhibitors,antiinterleukin6 receptor monoclonal antibody, antiCD20 antibodies rutximab and other drugs. They are prescribed for the treatment of rheumatoid arthritis, ankylosing  spondylitis,systemic lupus erythematosus and other autoimmune disease.The use of biological agents should pay attention to safety. It is necessary to screen tuberculosis and exclude active infections and cancer before the use of biologic agents. Reduction dose or stopping biological drug need to be discussed.

Key words: biological products, tumor necrosis factors, arthritis, rheumatoid; , spondylitis